Haratani K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non- small-cell lung cancer based on t790m status after disease progression during EGFR-tki treatment. Here, EGFR is linked to non-small cell lung carcinoma.